The Munich Leukemia Laboratory researchers will use Illumina’s NovaSeq technology to sequence samples from its biobank of more than 500,000 cases. After sequencing, the researchers will use IBM’s Watson system to analyze this genomic data in an effort to develop personalized leukemia treatments.
The ultimate goal of the project is to develop a Watson-based prototype that can analyze genomic and phenotypic data to provide clinicians with decision support related to leukemia care.
“We at MLL are excited to combine our data and knowledge, IBM’s cognitive computing tools and Illumina’s new sequencing platform to create a new era of insights in leukemia biology that will also drive more personalized treatment strategies,” said Dr. Torsten Haferlach, cofounder and CEO of the Munich Leukemia Laboratory.
More articles on health IT:
72% of hospitals have compromised email credentials: 6 things to know
Google’s DeepMind to develop ‘Verifiable Data Audit’ for hospital partners
Study: Can GPS data identify patients with anxiety?
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.